JPS60218323A - 抗腫瘍性物質ｓｐｆ―１０００及びその製法 - Google Patents
抗腫瘍性物質ｓｐｆ―１０００及びその製法Info
- Publication number
- JPS60218323A JPS60218323A JP59072865A JP7286584A JPS60218323A JP S60218323 A JPS60218323 A JP S60218323A JP 59072865 A JP59072865 A JP 59072865A JP 7286584 A JP7286584 A JP 7286584A JP S60218323 A JPS60218323 A JP S60218323A
- Authority
- JP
- Japan
- Prior art keywords
- substance
- antitumor
- reaction
- culture
- medium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 91
- 239000000203 mixture Substances 0.000 title claims abstract description 47
- 238000002360 preparation method Methods 0.000 title abstract description 4
- 239000000126 substance Substances 0.000 claims abstract description 86
- 238000006243 chemical reaction Methods 0.000 claims abstract description 33
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims abstract description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229930182555 Penicillin Natural products 0.000 claims abstract description 15
- 241000194017 Streptococcus Species 0.000 claims abstract description 15
- 239000007864 aqueous solution Substances 0.000 claims abstract description 15
- 229940049954 penicillin Drugs 0.000 claims abstract description 15
- 238000002523 gelfiltration Methods 0.000 claims abstract description 14
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000000843 powder Substances 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 238000000354 decomposition reaction Methods 0.000 claims abstract description 5
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 claims abstract description 5
- 238000000862 absorption spectrum Methods 0.000 claims description 16
- 238000012258 culturing Methods 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 11
- 241000894006 Bacteria Species 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- 238000010521 absorption reaction Methods 0.000 claims description 5
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical group CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 claims description 4
- 108010088751 Albumins Proteins 0.000 claims description 4
- 102000009027 Albumins Human genes 0.000 claims description 4
- 229920000858 Cyclodextrin Polymers 0.000 claims description 4
- 239000001116 FEMA 4028 Substances 0.000 claims description 4
- 108010044091 Globulins Proteins 0.000 claims description 4
- 102000006395 Globulins Human genes 0.000 claims description 4
- 230000002378 acidificating effect Effects 0.000 claims description 4
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 4
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 4
- 229960004853 betadex Drugs 0.000 claims description 4
- 230000007935 neutral effect Effects 0.000 claims description 4
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims description 3
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 claims description 3
- 229960003067 cystine Drugs 0.000 claims description 3
- 230000003287 optical effect Effects 0.000 claims description 3
- 238000004458 analytical method Methods 0.000 claims description 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims 1
- 108700014839 Streptococcus SAGP Proteins 0.000 claims 1
- 230000001186 cumulative effect Effects 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 abstract description 32
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 abstract description 6
- 238000000921 elemental analysis Methods 0.000 abstract description 5
- 229910052757 nitrogen Inorganic materials 0.000 abstract description 5
- 239000000463 material Substances 0.000 abstract description 4
- 239000002246 antineoplastic agent Substances 0.000 abstract description 3
- 238000001914 filtration Methods 0.000 abstract description 3
- 239000000047 product Substances 0.000 abstract description 3
- 238000013019 agitation Methods 0.000 abstract description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 abstract 1
- 239000000706 filtrate Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 71
- 210000004027 cell Anatomy 0.000 description 55
- 239000002609 medium Substances 0.000 description 51
- 238000012360 testing method Methods 0.000 description 34
- 206010028980 Neoplasm Diseases 0.000 description 20
- 201000011510 cancer Diseases 0.000 description 17
- 239000000284 extract Substances 0.000 description 17
- 235000013372 meat Nutrition 0.000 description 15
- 238000003756 stirring Methods 0.000 description 15
- 229940041514 candida albicans extract Drugs 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 14
- 239000012138 yeast extract Substances 0.000 description 14
- 230000000694 effects Effects 0.000 description 12
- 241000193996 Streptococcus pyogenes Species 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 150000002500 ions Chemical class 0.000 description 10
- 239000002244 precipitate Substances 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 229920005654 Sephadex Polymers 0.000 description 7
- 239000012507 Sephadex™ Substances 0.000 description 7
- 239000001888 Peptone Substances 0.000 description 6
- 108010080698 Peptones Proteins 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 230000010261 cell growth Effects 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- 235000019319 peptone Nutrition 0.000 description 6
- 238000011218 seed culture Methods 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 229940056360 penicillin g Drugs 0.000 description 5
- 206010003445 Ascites Diseases 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 4
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 4
- 235000011130 ammonium sulphate Nutrition 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 239000001506 calcium phosphate Substances 0.000 description 4
- 229910000389 calcium phosphate Inorganic materials 0.000 description 4
- 235000011010 calcium phosphates Nutrition 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000005342 ion exchange Methods 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 4
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 239000007621 bhi medium Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000005917 in vivo anti-tumor Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- -1 proform Chemical compound 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108010059892 Cellulase Proteins 0.000 description 2
- 238000011765 DBA/2 mouse Methods 0.000 description 2
- 241001669680 Dormitator maculatus Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 229910018104 Ni-P Inorganic materials 0.000 description 2
- 229910018536 Ni—P Inorganic materials 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 2
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 210000003850 cellular structure Anatomy 0.000 description 2
- 229940106157 cellulase Drugs 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 229910002570 KH2PO4-Na2HPO4 Inorganic materials 0.000 description 1
- 208000006268 Sarcoma 180 Diseases 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000005918 in vitro anti-tumor Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 239000012629 purifying agent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Compounds Of Unknown Constitution (AREA)
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59072865A JPS60218323A (ja) | 1984-04-13 | 1984-04-13 | 抗腫瘍性物質ｓｐｆ―１０００及びその製法 |
| CA000459394A CA1237085A (en) | 1983-08-01 | 1984-07-20 | Spf-100 and process for the preparation thereof |
| GB08418745A GB2146028B (en) | 1983-08-01 | 1984-07-23 | Spf-100 and process for the preparation thereof |
| DE19843428017 DE3428017A1 (de) | 1983-08-01 | 1984-07-30 | Spf-100 und verfahren zu seiner herstellung |
| CH3684/84A CH663033A5 (fr) | 1983-08-01 | 1984-07-30 | Substance-melange dite ''spf-100'' et procede pour sa preparation. |
| FR8412119A FR2550223B1 (fr) | 1983-08-01 | 1984-07-31 | Spf-100 et procede de preparation |
| KR1019840004559A KR850002276A (ko) | 1983-08-01 | 1984-07-31 | Spf-100의 제조방법 |
| NL8402388A NL8402388A (nl) | 1983-08-01 | 1984-07-31 | Geneesmiddel spf-100 en werkwijze voor de bereiding hiervan. |
| SE8403914A SE461532B (sv) | 1983-08-01 | 1984-07-31 | Cancermotverkande och immunaktiverande aemne (spf-100) |
| US06/746,514 US4656037A (en) | 1983-08-01 | 1985-06-19 | SPF-100 and process for the preparation thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59072865A JPS60218323A (ja) | 1984-04-13 | 1984-04-13 | 抗腫瘍性物質ｓｐｆ―１０００及びその製法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS60218323A true JPS60218323A (ja) | 1985-11-01 |
| JPH0155274B2 JPH0155274B2 (enrdf_load_stackoverflow) | 1989-11-22 |
Family
ID=13501654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59072865A Granted JPS60218323A (ja) | 1983-08-01 | 1984-04-13 | 抗腫瘍性物質ｓｐｆ―１０００及びその製法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS60218323A (enrdf_load_stackoverflow) |
-
1984
- 1984-04-13 JP JP59072865A patent/JPS60218323A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0155274B2 (enrdf_load_stackoverflow) | 1989-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS608117B2 (ja) | 新生理活性物質エステラスチンおよびその製造法 | |
| JPH03187389A (ja) | 新規な免疫抑制剤化合物 | |
| IE51590B1 (en) | Glycoproteins | |
| JPS61158997A (ja) | ポリペプチド抗生物質 | |
| JPS61148189A (ja) | Ｃｌ−１５７７ｄおよびｃｌ−１５７７ｅ抗生／抗腫瘍化合物およびそれらの製法 | |
| JPH01112989A (ja) | Ａｂ−００６抗生物質及びその製造方法 | |
| US4209507A (en) | Novel anti-tumor substance and preparation thereof | |
| JPS61216692A (ja) | Ｃｌ‐１５７７‐ｂ↓４化合物およびその製法 | |
| US4656037A (en) | SPF-100 and process for the preparation thereof | |
| JPS60259191A (ja) | Ｃｌ−１７２４抗微生物／抗腫瘍化合物、その製造および用途 | |
| JPS60218323A (ja) | 抗腫瘍性物質ｓｐｆ―１０００及びその製法 | |
| US3089816A (en) | Lemacidine and process for its manufacture | |
| EP0024206A2 (en) | Antitumor substance, composition comprising it and process for preparing said substance | |
| JPS6030689A (ja) | 生理活性物質ｓｐｆ−１及びその製法 | |
| JPH0155276B2 (enrdf_load_stackoverflow) | ||
| JPS60218324A (ja) | 生理活性物質ｓｐｆ−２及びその製法 | |
| JPS6287521A (ja) | 抗腫瘍性物質ｓｐｆ−１００−ｆ２及びその製法 | |
| JPH0156077B2 (enrdf_load_stackoverflow) | ||
| JPS6047686A (ja) | 抗インフルエンザウイルス物質アガラクチンおよびその製造法 | |
| JPS6216426A (ja) | 抗腫瘍性成分ｓｐｆ−１０及びその製法 | |
| JPH03184995A (ja) | 抗腫瘍剤 | |
| JPH01299264A (ja) | 新規物質ｆｌ−６５７ｃ及びその製造法 | |
| JPH01216927A (ja) | 抗腫瘍剤 | |
| JPS6030677A (ja) | ストレプトコツカス属細菌の培養法 | |
| JPS6326994B2 (enrdf_load_stackoverflow) |